Observational Study: Dysphagia in HD
A Study of Swallowing Changes in People with Huntington’s Disease Taking Chorea Medications
| What is this study? | This study looks at swallowing function (dysphagia) in people with Huntington’s disease who are taking medications commonly used to treat chorea, including VMAT2 inhibitors and dopamine receptor antagonists. Swallowing problems are very common in Huntington’s disease and can lead to serious complications. The goal of this study is to understand whether these routinely prescribed medications may improve, worsen, or have no effect on swallowing over time. No treatments are assigned by the study. All medications are prescribed as part of routine clinical care. |
| Who can participate? | • Adults 18 years and older • Clinical or genetic diagnosis of Huntington’s disease • Currently taking a VMAT2 inhibitor, a dopamine receptor antagonist, or both |
| What is required? | Participants will complete three study visits over about six months. At each visit, they will complete a swallowing questionnaire, brief neurologic and cognitive assessments, and a review of current medications. Some follow-up visits may be done virtually. No study medications are given. |
| How long does it take? | There are three visits (baseline, about 3 months, and about 6 months). Each visit takes approximately 45 minutes. |
| Contact | Ali Zare Dehnavi at [email protected] or (507) 218-6969 |